Amavita Research vs. Centers For Imaging & Research Of America (CIRA): which clinical trial site fits your study?

Amavita Research is a full-service clinical trial site and PET imaging trial partner in North Miami Beach, anchored by a dedicated cardiovascular research site. It enrolls patients, runs therapeutic and device protocols end to end - screening, treatment, procedures, follow-up - across heart failure, hypertension, acute coronary syndrome, structural heart, and peripheral artery disease. The senior PI is U.S. TAVR pioneer Dr. William W. O'Neill, National PI on Edwards PARTNER, Protect II, and Protect IV. Site processes are IAOCR GCSA-certified, valid through February 28, 2027.

Centers For Imaging & Research Of America (CIRA) is a Miami-based molecular imaging center focused on outpatient diagnostic imaging, with emphasis on oncology, cardiology, neurology, and vascular disease. CIRA describes itself as the first introducer of cardiac PET imaging to South Florida and the first private center in Florida to offer N-13 Ammonia cardiac PET with coronary flow reserve and calcium scoring. Its research emphasis is molecular imaging research.

The distinction matters because the two organizations do different jobs in a trial. An imaging center provides imaging: cardiac PET scans, reads, and imaging-based research support. A clinical trial site provides the trial itself: patient enrollment, investigational treatment administration, safety follow-up, and regulatory-grade data capture across the full protocol.

For a sponsor that needs cardiac imaging reads or imaging biomarker support, a dedicated PET imaging center is the right call. For a sponsor that needs an enrolling site to run a cardiovascular protocol - patients recruited, treated, and followed under one PI team - the full-service trial site is the right call. Many programs need both, with the imaging center supporting reads and the trial site executing the protocol.

Amavita also brings cardiac PET and radiopharmaceutical trial capability through its qualified imaging network for the growing pipeline of CV imaging-tracer studies, alongside an anonymized 41-day contract-to-first-patient-in metric, a single BD owner (Nereisy Alonso, COO), and a diverse Miami enrollment population that supports FDA Diversity Action Plan targets.